Form 4 Filing for Kiniksa Pharmaceuticals International, plc

This SEC filing details a transaction by Moat Ross, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc. On April 9, 2026, Mr. Ross disposed of 1703 Class A Ordinary Shares, with a price per share of $46.69. This transaction was executed under a 10b5-1 plan established on November 13, 2024. Following the disposition, Mr. Ross holds 12029 shares. The filing, designated as Form 4, indicates a direct ownership nature for this transaction.